CLYM116 Phase 1 data backs every-12-week dosing plan
Initial Phase 1 results for CLYM116 in healthy volunteers reported robust biomarker suppression, favorable safety, and a long half-life supporting every-12-week dosing; Phase 2 NAVIGATE-2 will confirm ahead of Phase 3.
Initial Phase 1 results for CLYM116 in healthy volunteers showed strong APRIL and immunoglobulin suppression, a favorable safety profile and a long half-life that supports dosing every 12 weeks. The ongoing Phase 2 NAVIGATE-2 study is intended to confirm those findings and support rapid progress to Phase 3.